Journal of Cardiovascular Pharmacology

NOVEMBER 21, 2023

Abstract: Transcatheter aortic valve replacement (TAVR) is an interventional procedure performed in patients with severe aortic stenosis and often required perioperative antiplatelet therapy. Most previous studies have focused on antiplatelet therapy following TAVR.

Aortic valve 40

Aortic valve Aortic TAVR Myocardial Infarction 40

Circulation: Cardiovascular Interventions

OCTOBER 22, 2023

Background:Atherosclerotic cardiovascular disease (ASCVD) is highly prevalent in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVR). Exposure of interest was PVD. Primary outcome was all-cause mortality.

Aortic valve 40

Aortic valve Aortic TAVR Outcomes 40

Open Heart

JANUARY 19, 2023

Objective Postprocedural ischaemic and bleeding risks after transcatheter aortic valve replacement (TAVR) remain a major concern. We aimed to assess the accuracy of percutaneous coronary intervention (PCI)-derived models and the performance of a recalibrated model that included variables more applicable to TAVR.

Aortic valve 52

Aortic valve TAVR Aortic Myocardial Infarction 52

DAIC

FEBRUARY 29, 2024

ET Murphy Ballroom 4 ACC.24 24 planners note that attendees can gain insights from key clinical trials presented at ACC.24 24 and how those may impact clinical practice and patient care in this deep dive clinical trial session.

Aortic valve 103

Aortic valve Myocardial Infarction Aortic Blood Pressure 103

Dr. S. Venkatesan MD

APRIL 22, 2024

This typically occurs after an inferior posterior myocardial infarction, drug-induced CHB. Currently, with the arrrival of TAVR, CHB has beceome a glamorous complication and is getting wider attention. Management of conduction disturbances associated with transcatheter aortic valve replacement: JACC Scientific Expert Panel.

Pacemaker 40

Pacemaker Aortic valve TAVR Myocardial Infarction 40

Cardiology Update

APRIL 9, 2024

EMPACT-MI 1 ( NCT04509674 ) studied the effects of empagliflozin in patients who have experienced myocardial infarction (MI). SMART 4 ( NCT04722250 ) studied patients with severe aortic stenosis and a small aortic annulus who underwent transcatheter aortic valve replacement (TAVR). April 6, 2024.

Myocardial Infarction 52

Myocardial Infarction Angina Aortic valve Coronary Artery Disease 52

Open Heart

JULY 23, 2024

Objective To compare long-term cardiovascular (CV) outcomes between men and women with aortic stenosis (AS) undergoing aortic valve replacement (AVR) by the type of valve implant. In the TAVR cohort, men suffered a higher risk of death (HR: 1.24; 95% CI: 1.07 to 1.69, p<0.001) was observed in men.

Aortic valve 52

Aortic valve Aortic Stenosis TAVR 52